Alchemab Therapeutics: Funding, Investors & Team (Sep 2026)
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
Alchemab Therapeutics has raised $151M across 5 funding rounds on record, the most recent a Series A of $33.6M announced in Jul 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Alchemab Therapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2026.
Alchemab Therapeutics Funding Rounds
Alchemab Therapeutics raised $82.8M in a Series A announced in Apr 2021.
1.7 years later, an undisclosed round of $2.1M was announced in Dec 2022.
1.5 years later, an undisclosed round of $600k was announced in Jun 2024.
1.3 years later, a Series A of $32.0M was announced in Sep 2025.
10 months later, a Series A of $33.6M was announced in Jul 2026.
Alchemab Therapeutics Investors
12 investors are recorded in total; the 5 named above are those the record identifies.
Alchemab Therapeutics Founders and Leadership Team
Contact details for the Alchemab Therapeutics team: 2 of 3 have an email address on file.
Start 14-day free trial →Alchemab Therapeutics Funding Compared to Other Biotechnology Startups
Alchemab Therapeutics' latest round of $33.6M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Alchemab Therapeutics in Biotechnology and London
Companies Similar to Alchemab Therapeutics
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Scarlet Therapeutics is developing the novel red blood cell-based therapeutics (tRBCs) generation platform.
Alchemab Therapeutics Funding FAQs
What does Alchemab Therapeutics do?
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
How much funding has Alchemab Therapeutics raised?
Alchemab Therapeutics has raised $151M across 5 rounds on record. The most recent is a Series A of $33.6M announced in Jul 2026.
When did Alchemab Therapeutics last raise funding?
Alchemab Therapeutics' most recent funding round on record is a Series A of $33.6M, announced in Jul 2026.
Who has invested in Alchemab Therapeutics?
Investors on record for Alchemab Therapeutics include RA Capital Management, British Business Bank, Eli Lilly, Michael J. Fox Foundation, DCVC Bio. FundedIQ records 12 investors in total.
Who founded Alchemab Therapeutics?
FundedIQ lists Jane Osbourn (Founder) at Alchemab Therapeutics.
Who is the CEO of Alchemab Therapeutics?
Alex Leech is listed as CEO at Alchemab Therapeutics.
Where is Alchemab Therapeutics headquartered?
Alchemab Therapeutics is based in London, England, United Kingdom.
How many employees does Alchemab Therapeutics have?
Alchemab Therapeutics is in the 51-100 employee band.
When was Alchemab Therapeutics founded?
Alchemab Therapeutics was founded in 2019.
How does Alchemab Therapeutics' funding compare to other Biotechnology startups?
Alchemab Therapeutics' latest round of $33.6M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Alchemab Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Alchemab Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.